Reports from the ELNet workshops on the standardization of FC in MDS provide recommendations for implementing FC and propose minimal criteria for the diagnosis and prognostic evaluation of MDS and other cytopenias.
Initial Screening for MDS With FC
Because MDS comprises a heterogeneous group of myeloid neoplasms, it is unlikely that a single specific marker can discriminate MDS from other cytopenias. Therefore, the presence of multiple aberrancies has a higher predictive value for MDS than single aberrancies. [6] [7] [8] [9] As shown in a multicenter study on behalf of the ELNet, application of only 4 parameters enables low-risk MDS without other specific markers (ie, cytogenetics or ring sideroblasts) to be distinguished from nonclonal cytopenias. 10 The cardinal parameters within this score are
1. An increased percentage of CD34 + progenitor cells of nucleated cells in a bone marrow sample (≥2%) 2. A decreased number of progenitor B cells within the CD34 + compartment (≤5%) 3. A decreased or increased CD45 expression on myeloid progenitor cells compared with that of reference lymphocytes (≤4.0 or ≥7.5) 4. A decreased sideward light scatter (SSC) of neutrophils compared with that of reference lymphocytes (≤6.0)
Displayed reference ranges were determined from a large cohort of patients with nonclonal cytopenia. In assessing whether data of a particular patient were beyond the reference range, the presence of 2 or more of these specific aberrancies identified 70% of patients with low-risk MDS with a specificity of 93%. 10 This simple diagnostic score is a start; however, for reliable clinical application in a single patient, its sensitivity may need improvement.
One pitfall of this score is hemodilution that may cause underestimation of the progenitor compartment. Moreover, a relative decrease in B-cell progenitors is also seen in the elderly population without MDS, and can result from an increase in myeloid progenitor cells, especially in high-risk MDS. Furthermore, myeloid progenitors may be aberrantly CD34
-. Reference ranges for CD45 and SSC in a particular center may differ slightly because of differences in fluorochromes and instrument settings.
Additional Means to Assess Dysplasia With FC
Assessment of an accumulation of FC aberrancies beyond the 4 cardinal parameters might strongly enhance sensitivity, and hence support the diagnosis of MDS. The accumulation of FC aberrancies is reflected by the FC scoring system. An overview of these parameters is given in the following paragraphs and assists in clinical reporting (Tables 1 and 2 ). For example, discrimination of normal and abnormal myeloid progenitor cells can be assessed through evaluation of several markers such as CD34, CD117, HLA-DR, and lineage infidelity markers. Simultaneous analysis of the maturing myelomonocytic compartment adds valuable information. 6, [11] [12] [13] Additionally, analysis of erythroid differentiation might provide valuable information, particularly within low-risk MDS. 11, [13] [14] [15] Table 3 summarizes current agreement on the FC parameters that are considered most relevant for diagnosing MDS.
Few applications are available for FC analysis of the megakaryocytic lineage. A recent publication introduces the analysis of platelets in peripheral blood as a reliable substitute. 16 Validation of this procedure is currently ongoing. Standard morphology and immunohistochemistry are therefore still recommended for analyzing dysplasia in this cell lineage.
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Recommendations for Evaluation of Dysplasia in the Immature and Maturing Myelomonocytic Compartment
Recommendations on technical issues, such as sample preparation, instrument setup and quality assessment, acquisition of data (eg, number of events), and gating strategy, are extensively described in the ELNet reports. 3, 4 No standard panels are available within the ELNet working group at the moment.
Evaluation of dysplasia necessitates knowledge of expression levels in appropriate bone marrow controls. Bone marrow aspirates of age-matched healthy volunteers and other nonclonal cytopenic patients should be available. 3, [18] [19] [20] For standardization of analysis and interpretation of results between patients and controls, a standardized gating strategy, color code for subpopulations, and synchronization of dotplot display (identical x and y axes orientation for same antibodies) are recommended. 22 This immature cell compartment is very heterogeneous; therefore, antibody combinations such as CD45/CD34/CD117/HLA-DR and CD45/ CD34/CD123/HLA-DR are instrumental in distinguishing myeloid progenitor cells from other populations (eg, B-cell precursors, plasma cells, monoblasts, basophils, erythroblasts, and plasmacytoid dendritic cell precursors) that might show overlapping CD45 and SSC features. 3 Granular progenitors or degranulated neutrophils may overlap and should be defined accordingly (Figure 1 ). Antibody combinations, including markers such as CD15, CD24, CD10, CD11b, and HLA-DR, can be useful in this respect.
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Evaluation of Dysplasia in the Immature Myeloid Progenitor Compartment
In low-risk MDS in particular, percentages of progenitor cells are low. However, dysplastic immature myeloid progenitors in MDS may have an aberrant immunophenotype that distinguishes them from normal progenitors. Some of the observed aberrancies in the immature myeloid compartment in MDS are an abnormal intensity or lack of expression of CD45, CD34, CD117, HLA-DR, CD13, and CD33; asynchronous presence of CD11b; and/or the expression of lineage infidelity markers such as CD5, CD7, or CD56 (extended list in Table 3) . 6, 8, 11, 12, [23] [24] [25] [26] [27] An example of aberrant homogeneously high expression of CD117 is depicted in Figures 2 and 3 . These markers should be analyzed not only on CD34 + progenitor cells but also among CD117 + /CD34
-precursors, because CD34 may be aberrantly lost.
Note that several markers, such as CD7 and CD56, can be expressed on a small subset of normal immature myeloid progenitor cells, especially in recovering hematopoiesis. 8, 28 This requires knowledge of expression levels in appropriate bone marrow controls. Figure 2 ).
Evaluation of Dysplasia in the Neutrophil Compartment
The number of maturing neutrophils partly reflects the ability of the progenitor compartment to proliferate and differentiate, thereby supporting successful hematopoiesis. A decreased amount of neutrophils might indicate disturbed granulopoiesis. One of the most frequently reported FC aberrancies in the maturing neutrophil compartment is an abnormally decreased SSC reflecting hypogranularity. 3, 11 The SSC of maturing neutrophils should be expressed as a ratio relative to that obtained for lymphocytes as an internal reference. 10 Next to decreased SSC, dysplastic neutrophils can display increased or decreased expression of antigens or an aberrant relationship among 2 or more antigens, such as aberrant relationships between CD13 and CD11b and/or CD13 and CD16 and between CD15 and CD10 (Table 3, Figure 2 ). Additional dysplastic features of neutrophils are summarized in Table 3 . Table 2 for conclusion in words with advice to clinicians how to interpret the results. b Choice for "A or B" and "B or C" depends on the kind and number of aberrancies that are encountered (see Table 4 ). Note that FC results should be part of an integrated diagnostic approach, including cytology, bone marrow immunohistochemistry, cytogenetics, and fluorescence in situ hybridization analysis in selected cases. Note that because of genetic polymorphisms, some markers such as CD16 or CD33 may show nonaberrantly low expression levels. Furthermore, decreased expression of CD16 and CD11b has been reported to coincide with apoptosis. Assessment of the CD11b versus CD16 pattern next to that of CD16 versus CD13 can be helpful in this respect. Moreover, loss of glycosyl-phosphatidyl-inositol (GPI)-associated cell surface proteins, such as paroxysmal nocturnal hemoglobinuria (PNH), can cause loss of CD16 expression. 4, 25, [29] [30] [31] [32] [33] A neutrophil-associated marker recently introduced as potentially indicative of MDS is the intracellular myeloid nuclear-derived antigen (MNDA), which displays a marked down regulation in MDS. Interestingly, the combined use of standard FC and MNDA improved sensitivity of correct identification of MDS by FC from 78% to 91% (specificity decreased from 91%-81%).
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Evaluation of Dysplasia in the Monocytic Compartment
Morphologic assessment of dysmonopoiesis in MDS is difficult unless marked monocytosis is present. In FC, monocytes can be defined based on their CD45 expression (intermediate-bright Notably, CD14 recognizes a GPI-anchored protein that can be absent because of coexistence of PNH. Maturing neutrophils with an abnormally low SSC can interfere in the analysis of the monocytic population. The previous paragraph describes how these subpopulations might be separated. Aberrancies of interest in the monocytic lineage are the proportion of an abnormal distribution of maturation stages, abnormal relationships of HLA-DR versus CD11b, abnormal intensity of CD13, and overexpression of CD56 (recommended aberrancies in Table 3 ).
CD56 (and CD2) may even contribute to discriminate chronic myelomonocytic leukemia from MDS/myeloproliferative neoplasms. [36] [37] [38] A caveat is that CD56 expression is frequently seen on hematopoiesis regeneration, activation, and inflammatory responses, and therefore the clinical context is of utmost importance. Activation often coincides with upregulation of HLA-DR and CD64. 6 ,28,36,39
Figure 1 Heterogeneity of progenitor compartments as defined by diminished CD45 (CD45 dim ) and low sideward light scatter (SSC). The graphs in the upper row show CD45-SSC profiles of 3 bone marrow samples of a control and myelodysplastic syndromes (MDS) cases (unique patient number 1 [UPN1], UPN2, and UPN3, respectively). CD45 is depicted on x axes and SSC on y axes. Cells residing in the CD45
dim SSC low gates in the upper row plots are highlighted in the bottom row. Erythroid cells are depicted in red, neutrophils in pink, monocytes in orange, and lymphocytes in green. Hypogranular neutrophils interfere in the progenitor compartment in these MDS cases (UPN2 and UPN3). The progenitor cells are depicted in blue: dark blue for myeloid cells and pale blue for B-cell precursors; the latter are not present in the MDS cases UPN2 and UPN3. Basophils are depicted in purple, and any other undefined cell is in grey.
Evaluation of Dysplasia in the Erythroid Compartment
The erythroid population can be defined by its very dim to negative CD45 expression and low FSC and SSC properties. 20 Commonly applied markers are CD45, CD71, CD235a, CD36, CD117, and less frequently the endoglin marker CD105. 8, 11, 14, 15, 40 One of the most frequently observed aberrancies (80% of low-risk MDS) is an increased number of erythroid progenitors associated with a larger proportion of immature erythroid cells (CD117   +   ) . Otherwise, a decrease in erythroid progenitors from apoptosis or erythropoietin deficiency can be observed. In approximately 70% of the patients, asynchronous expression of CD71 versus CD235a and/ or decreased CD36 have been reported. 8, 11, 14, 15, 40 Examples are displayed in Figure 4 . Note that the nucleated erythroid cells are generally studied after lysis of mature erythrocytes with ammonium chloride; this procedure may affect features of nucleated erythroid cells that may falsely be assigned to dysplasia. Another well-known feature of erythroid dysplasia is the presence of ring sideroblasts. These cells are definitely of diagnostic relevance; currently, however, FC has no additional value for quantifying ring sideroblasts.
FC Within an Integrated Diagnostic Report
WHO 2008 recommendations recognize the presence of 3 or more FC aberrancies in maturation patterns as indicative of MDS. 5 Furthermore, increased percentages of progenitor cells and aberrant marker expression indicate dysplasia. In line with this, it is recommended that the results of analysis of dysplasia with FC be reported in a descriptive manner. A report should contain the following:
1. Percentage of myeloid progenitors, including description of aberrancies when present 2. Absence or presence of dysgranulopoiesis (either decreased SSC and/or 2 other aberrancies) 3. Absence or presence of dysmonocytopoiesis (either CD56 expression and/or 2 other aberrancies)
These results are translated into a conclusion that elucidates whether the immunophenotypic profile is "A: not-fitting," "B: suggestive of," or "C: indicative of" MDS taking into account the diagnostic score based on the 4 cardinal parameters ( Table  1) . Note that FC results should be part of an integrated diagnostic approach, including cytology, bone marrow immunohistochemistry, cytogenetics, and fluorescence in situ hybridization analysis in selected cases (Table 4) .
Current Flow Cytometric Scoring Systems in the Diagnosis of MDS
Current guidelines were developed when 4-color FC was the mainstay. Nowadays, many institutes apply 6-to 8-color FC. Recommended antibody combinations remain similar; however, some can be combined, thereby revealing new information on relationships between different cellular compartments 41 ( Figure 2 ). Despite this, it remains a struggle to dissect MDS from other conditions with cytopenia and normal karyotype in some cases. Numerous FC Thus far, the only validated prognostic FC score is the FC scoring system by Wells et al. 8, 9, 27, 45 This score weighs the percentage of progenitor cells and their aberrancies and the amount of aberrancies in the maturing compartment. The flow scores are rather heterogeneous within the subgroups or risk groups of the WHO, IPSS-R, and WPSS. This suggests that FC can identify patients with worse prognosis within validated risk categories; this concept is currently under evaluation.
FC in Predicting and Monitoring Treatment Response
Furthermore, FC analysis of bone marrow cells in low and intermediate-1 (int-1) risk MDS is instrumental to identify subgroups with distinct clinical behavior regarding transfusion dependency and progression. A clinical decision model was designed using the presence of aberrant myeloid progenitors determined by FC in the bone marrow in combination with endogenous erythropoietin levels to predict response to growth factor treatment. Patients with low and int-1 risk MDS with normal myeloid progenitors and low endogenous erythropoietin have the highest probability of responding to growth factor treatment. 46 In addition, aberrant marker expression on myeloid progenitors cells by FC identifies patients who may not benefit from treatment with hypomethylating agents such as azacitidine in int-2 and high-risk MDS (C. Alhan, MD, unpublished data, 2013). 47 Studies are currently ongoing to implement FC by intensive monitoring in selecting patients who may benefit from prolonged treatment with azacitidine.
Conclusions
In MDS, FC is regarded as a new key player, and is therefore a recommended tool for diagnosing MDS if performed according to the ELNet guidelines. 3, 4 However, it should only be applied as a part of an integrated diagnostic approach. Repeated FC assessments are highly recommended, not only in inconclusive cases but also as part of new prognostic scoring systems. Finally, current investigations focus on the role of FC in monitoring the disease course in patients with untreated, mainly lower-risk MDS, and during treatment with emerging new drugs to identify patients who may benefit from prolonged treatment of established and new drugs in low-and high-risk MDS. 
